Madrigal Pharmaceuticals, Inc. (MDGL) AI Stock Analysis

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapeutic candidates aimed at addressing cardiovascular, metabolic, and liver diseases. Central to its pipeline is resmetirom, a liver-directed selective thyroid hormone receptor agonist currently undergoing Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). In addition to resmetirom, the company is advancing MGL-3745, a backup compound designed to complement its primary therapeutic efforts. Madrigal Pharmaceuticals has established a collaborative partnership with Hoffmann-La Roche to enhance its capabilities in advancing innovative therapies from discovery through to commercialization. Headquartered in West Conshohocken, Pennsylvania, the company employs 915 people.

Madrigal generated revenue of $350,000 in FY2017, which expanded to $180.1M in FY2024 and reached $958.4M in FY2025, reflecting 432.1% revenue growth in FY2025. Gross margin stood at 96.5% in FY2024 and 94.1% in FY2025. Operating margin improved from -276.4% in FY2024 to -31.3% in FY2025, while research and development expense totaled $388.5M in FY2025. Net loss narrowed from -$465.9M (EPS of -$22.11) in FY2024 to -$288.3M (EPS of -$12.75) in FY2025. Over the trailing twelve months, revenue reached $1.28B with a profit margin of -25.3% and EPS of -$12.85. In the latest quarter ended June 30, 2026, quarterly revenue grew 71.2% year-over-year.

As of June 30, 2026, Madrigal held $838.8M in cash and short-term investments and $347.8M in total debt, resulting in net cash of $491.0M. The company reported total assets of $1.24B, shareholders' equity of $523.7M, a current ratio of 3.20, and a debt-to-equity ratio of 0.66. Operating cash flow was -$189.6M and free cash flow was -$190.0M in FY2025. Capital expenditures were $467,000 in FY2025, while share count increased 70.7% over 5 years.

With a market capitalization of $10.39B and enterprise value of $11.36B, Madrigal trades at a forward P/E of 78.1x, higher than the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 8.1x compared to the median of its US-listed Healthcare peers of 4.1x, alongside an EV-to-revenue ratio of 8.8x and price-to-book ratio of 22.6x. Over the past year, the stock gained 1.7%, trailing the S&P 500 (SPY) return of 16.8%. Over 5 years, the shares rose 421.9%, outpacing the SPY return of 83.0%.

Wall Street coverage consists of 15 Strong Buy, 3 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $685.78, representing 52.5% upside from the last close of $449.74. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$6.49 on revenue of $1.53B. For the next fiscal year, 4 analysts estimate EPS will turn positive to $9.62 on revenue of $2.12B. Over the last four quarters, Madrigal beat EPS estimates 2 times. The next earnings date is November 3, 2026.

This page is an AI-written research summary of Madrigal Pharmaceuticals, Inc. (MDGL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MDGL income statement, MDGL balance sheet, MDGL key metrics, MDGL analyst forecast, MDGL chart. See the MDGL stock overview for the latest quote and news.